FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2147403954> ?p ?o ?g. }

• W2147403954 abstract "Background It is well known that physical exercise can trigger asthma symptoms and can induce bronchial obstruction in people without clinical asthma. International guidelines on asthma management recommend the use of beta2‐agonists at any stage of the disease. At present, however, no consensus has been reached about the efficacy and safety of beta2‐agonists in the pretreatment of exercise‐induced asthma and exercise‐induced bronchoconstriction. For the purpose of the present review, both of these conditions are referred to by the acronymous EIA, independently from the presence of an underlying chronic clinical disease. Objectives To assess the effects of inhaled short‐ and long‐acting beta2‐agonists, compared with placebo, in the pretreatment of children and adults with exercise‐induced asthma (or exercise‐induced bronchoconstriction). Search methods Trials were identified by electronic searching of the Cochrane Airways Group Specialised Register of Trials and by handsearching of respiratory journals and meetings. Searches are current as of August 2013. Selection criteria We included randomised, double‐blind, placebo‐controlled trials of any study design, published in full text, that assessed the effects of inhaled beta2‐agonists on EIA in adults and children. We excluded studies that did not clearly state diagnostic criteria for EIA. Data collection and analysis We used standard methodological procedures as expected by The Cochrane Collaboration. Main results We included 53 trials consisting of 1139 participants. Forty‐eight studies used a cross‐over design, and five were performed in accordance with a parallel‐group design. Forty‐five studies addressed the effect of a single beta2‐agonist administration, and eight focused on long‐term treatment. We addressed these two different intervention regimens as different comparisons. Among primary outcomes for short‐term administration, data on maximum fall in forced expiratory volume in 1 second (FEV1) showed a significant protective effect for both short‐acting beta‐agonists (SABA) and long‐acting beta‐agonists (LABA) compared with placebo, with a mean difference of ‐17.67% (95% confidence interval (CI) ‐19.51% to ‐15.84%, P = 0.00001, 799 participants from 72 studies). The subgroup analysis of studies performed in adults compared with those performed in children showed high heterogeneity confined to children, despite the comparable mean bronchoprotective effect. Secondary outcomes on other pulmonary function parameters confirmed a more positive and protective effect of beta2‐agonists on EIA compared with placebo. Occurrence of side effects was not significantly different between beta2‐agonists and placebo. Overall evaluation of the included long‐term studies suggests a beta2‐agonist bronchoprotective effect for the first dose of treatment. However, long‐term use of both SABA and LABA induced the onset of tolerance and decreased the duration of drug effect, even after a short treatment period. Authors' conclusions Evidence of low to moderate quality shows that beta2‐agonists, both SABA and LABA, when administered in a single dose, are effective and safe in preventing EIA. Long‐term regular administration of inhaled beta2‐agonists induces tolerance and lacks sufficient safety data. This finding appears to be of particular clinical relevance in view of the potential for prolonged regular use of beta2‐agonists as monotherapy in the pretreatment of EIA, despite the warnings of drug agencies (FDA, EMA) regarding LABA." @default.
• W2147403954 created "2016-06-24" @default.
• W2147403954 creator A5030629710 @default.
• W2147403954 creator A5031928111 @default.
• W2147403954 creator A5043192106 @default.
• W2147403954 creator A5064146791 @default.
• W2147403954 creator A5071868716 @default.
• W2147403954 creator A5076221168 @default.
• W2147403954 creator A5083167500 @default.
• W2147403954 date "2013-10-02" @default.
• W2147403954 modified "2023-09-27" @default.
• W2147403954 title "Beta₂-agonists for exercise-induced asthma" @default.
• W2147403954 cites W1552871215 @default.
• W2147403954 cites W1557879742 @default.
• W2147403954 cites W156308815 @default.
• W2147403954 cites W1614526394 @default.
• W2147403954 cites W1669289313 @default.
• W2147403954 cites W1893638090 @default.
• W2147403954 cites W1963846180 @default.
• W2147403954 cites W1966364214 @default.
• W2147403954 cites W1969241951 @default.
• W2147403954 cites W1971692913 @default.
• W2147403954 cites W1973213513 @default.
• W2147403954 cites W1973429665 @default.
• W2147403954 cites W1975777122 @default.
• W2147403954 cites W1976282279 @default.
• W2147403954 cites W1983976367 @default.
• W2147403954 cites W1986325326 @default.
• W2147403954 cites W1988431729 @default.
• W2147403954 cites W1991347458 @default.
• W2147403954 cites W1991452514 @default.
• W2147403954 cites W1994743507 @default.
• W2147403954 cites W1997940525 @default.
• W2147403954 cites W2003640527 @default.
• W2147403954 cites W2004613341 @default.
• W2147403954 cites W2008550143 @default.
• W2147403954 cites W2012060350 @default.
• W2147403954 cites W2012143160 @default.
• W2147403954 cites W2014473048 @default.
• W2147403954 cites W2016001381 @default.
• W2147403954 cites W2018353988 @default.
• W2147403954 cites W2019581290 @default.
• W2147403954 cites W2021712395 @default.
• W2147403954 cites W2024141629 @default.
• W2147403954 cites W2025874982 @default.
• W2147403954 cites W2028278714 @default.
• W2147403954 cites W2032026024 @default.
• W2147403954 cites W2037952886 @default.
• W2147403954 cites W2038086709 @default.
• W2147403954 cites W2042203262 @default.
• W2147403954 cites W2042617656 @default.
• W2147403954 cites W2043038102 @default.
• W2147403954 cites W2043444846 @default.
• W2147403954 cites W2046885994 @default.
• W2147403954 cites W2050875097 @default.
• W2147403954 cites W2052737408 @default.
• W2147403954 cites W2053171228 @default.
• W2147403954 cites W2056385860 @default.
• W2147403954 cites W2058590939 @default.
• W2147403954 cites W2060686170 @default.
• W2147403954 cites W2062079109 @default.
• W2147403954 cites W2064344412 @default.
• W2147403954 cites W2066010169 @default.
• W2147403954 cites W2067220078 @default.
• W2147403954 cites W2067669835 @default.
• W2147403954 cites W2069385644 @default.
• W2147403954 cites W2070175053 @default.
• W2147403954 cites W2070289515 @default.
• W2147403954 cites W2070348992 @default.
• W2147403954 cites W2070726071 @default.
• W2147403954 cites W2071055600 @default.
• W2147403954 cites W2071675278 @default.
• W2147403954 cites W2071891491 @default.
• W2147403954 cites W2072613930 @default.
• W2147403954 cites W2073857653 @default.
• W2147403954 cites W2078149605 @default.
• W2147403954 cites W2078534806 @default.
• W2147403954 cites W2081751821 @default.
• W2147403954 cites W2083121402 @default.
• W2147403954 cites W2083855277 @default.
• W2147403954 cites W2084617508 @default.
• W2147403954 cites W2088747023 @default.
• W2147403954 cites W2089124540 @default.
• W2147403954 cites W2090495361 @default.
• W2147403954 cites W2090705064 @default.
• W2147403954 cites W2090974883 @default.
• W2147403954 cites W2091333652 @default.
• W2147403954 cites W2091394537 @default.
• W2147403954 cites W2091760521 @default.
• W2147403954 cites W2093063293 @default.
• W2147403954 cites W2094486851 @default.
• W2147403954 cites W2094571946 @default.
• W2147403954 cites W2097229012 @default.
• W2147403954 cites W2097274392 @default.
• W2147403954 cites W2100279620 @default.
• W2147403954 cites W2101710269 @default.
• W2147403954 cites W2107437761 @default.
• W2147403954 cites W2107990055 @default.
• W2147403954 cites W2119011882 @default.
• W2147403954 cites W2126057158 @default.

• next